SLC5A2 and type 2 diabetes mellitus: We recognise that although observations from this analysis are generally consistent with renal-related effects in other trials with SGLT2 inhibitors, findings from this cohort with type 2 diabetes and established atherosclerotic CVD may not be generalisable to other groups of individuals.